{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T21:29:51Z","timestamp":1775856591220,"version":"3.50.1"},"reference-count":33,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Chronic hepatitis B (CHB) and type 2 diabetes mellitus (T2DM) frequently coexist. This study aimed to investigate the impact of T2DM and glycemic control on antiviral efficacy in CHB patients. Methods: This single-center, retrospective cohort study included treatment-na\u00efve CHB patients who initiated nucleos(t)ide analogue (NA) therapy between January 2019 and January 2024. The primary endpoint was a complete virological response (CVR), defined as achieving HBV DNA levels below 20 IU\/mL after 48 weeks of treatment. Results: The CHB + T2DM group (n = 81) demonstrated a significantly lower CVR rate than the CHB group (n = 106) (26.0% vs. 41.2%, p = 0.038). Multivariate analysis identified T2DM as an independent negative predictor of a CVR (OR = 0.400, 95% CI: 0.196\u20130.815, p = 0.012). Within the CHB + T2DM subgroup, adequate glycemic control (HbA1c &lt; 7%) was associated with a higher CVR (38.7% vs. 16.7%, p = 0.034). Patients newly diagnosed with diabetes at enrollment showed a higher rate of HBeAg loss than those with pre-existing diabetes (57.1% vs. 10.0%, p = 0.036). Regarding antiviral regimens, entecavir-treated CHB + T2DM patients had a lower CVR than CHB controls (18.8% vs. 46.2%, p = 0.015). Furthermore, tenofovir-based regimens showed a more favorable antiviral trend than entecavir in CHB patients with T2DM. Conclusions: Comorbid T2DM was an independent risk factor for impaired antiviral efficacy in CHB patients. Optimal glycemic control may improve virological outcomes. These findings suggest that the early diagnosis and management of T2DM could enhance antiviral treatment efficacy in CHB patients.<\/jats:p>","DOI":"10.3390\/jcm15051826","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:52:38Z","timestamp":1772207558000},"page":"1826","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diabetes Impairs the Virological Response in Patients with Chronic Hepatitis B: Glycemic Control as a Key Modifiable Risk Factor"],"prefix":"10.3390","volume":"15","author":[{"given":"Aoyi","family":"Li","sequence":"first","affiliation":[{"name":"Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 401336, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Han","sequence":"additional","affiliation":[{"name":"Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 401336, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanglin","family":"Xiao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 401336, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiling","family":"Deng","sequence":"additional","affiliation":[{"name":"Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 401336, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaojing","family":"Wen","sequence":"additional","affiliation":[{"name":"Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 401336, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Qiu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 401336, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiyu","family":"He","sequence":"additional","affiliation":[{"name":"Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 401336, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4557-0918","authenticated-orcid":false,"given":"Hong","family":"Ren","sequence":"additional","affiliation":[{"name":"Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 401336, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of Worldwide Prevalence of Chronic Hepatitis B Virus Infection: A Systematic Review of Data Published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet Lond. Engl."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","article-title":"Hepatitis B Virus Reactivation Associated with New Classes of Immunosuppressants and Immunomodulators: A Systematic Review, Meta-Analysis, and Expert Opinion","volume":"77","author":"Papatheodoridis","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104815","DOI":"10.1016\/j.antiviral.2020.104815","article-title":"HBV Replication Inhibitors","volume":"179","author":"Dousson","year":"2020","journal-title":"Antiviral Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B Reactivation Associated with Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.gastro.2022.10.008","article-title":"Current Best Practice in Hepatitis B Management and Understanding Long-Term Prospects for Cure","volume":"164","author":"Yardeni","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B\u2014Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"72","author":"Cornberg","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3350\/cmh.2021.0093","article-title":"Toward a Complete Cure for Chronic Hepatitis B: Novel Therapeutic Targets for Hepatitis B Virus","volume":"28","author":"Kim","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ajg.2011.45","article-title":"Three Years of Continuous Entecavir Therapy in Treatment-Na\u00efve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety","volume":"106","author":"Yuen","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/hep.24406","article-title":"Entecavir Treatment for Chronic Hepatitis B: Adaptation Is Not Needed for the Majority of Na\u00efve Patients with a Partial Virological Response","volume":"54","author":"Zoutendijk","year":"2011","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jhep.2009.12.036","article-title":"Long-Term Use of Entecavir in Nucleoside-Na\u00efve Japanese Patients with Chronic Hepatitis B Infection","volume":"52","author":"Yokosuka","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of Hepatocellular Carcinoma across a Biological Gradient of Serum Hepatitis B Virus DNA Level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/djn243","article-title":"Associations between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma","volume":"100","author":"Yang","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of Cirrhosis during Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B: A 5-Year Open-Label Follow-up Study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet Lond. Engl."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1053\/j.gastro.2008.07.008","article-title":"HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma","volume":"135","author":"Yuen","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jgh.12700","article-title":"Hepatitis B Virus Infection and Metabolic Syndrome: Fact or Fiction?","volume":"30","author":"Wang","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3350\/cmh.2022.0095","article-title":"Development and Prognosis of Hepatocellular Carcinoma in Patients with Diabetes","volume":"29","author":"Nakatsuka","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3892\/etm.2015.2537","article-title":"Association between Hepatitis B Virus Infection and Diabetes Mellitus: A Meta-Analysis","volume":"10","author":"Cai","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.3748\/wjg.v18.i42.6120","article-title":"Association of Chronic Viral Hepatitis B with Insulin Resistance","volume":"18","author":"Lee","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/cid\/cit603","article-title":"Increased Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients with Newly Diagnosed Diabetes: A Nationwide Cohort Study","volume":"57","author":"Huang","year":"2013","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/apt.13191","article-title":"Increased Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with New Onset Diabetes: A Nationwide Cohort Study","volume":"41","author":"Fu","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/hep.32716","article-title":"Glycemic Burden and the Risk of Adverse Hepatic Outcomes in Patients with Chronic Hepatitis B with Type 2 Diabetes","volume":"77","author":"Mak","year":"2023","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and Pathogenesis of Hepatitis B Virus Infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Fisicaro, P., Barili, V., Rossi, M., Montali, I., Vecchi, A., Acerbi, G., Laccabue, D., Zecca, A., Penna, A., and Missale, G. (2020). Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00849"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.it.2025.02.014","article-title":"Diabetes Can Impact Cellular Immunity in Solid Tumors","volume":"46","author":"Garstka","year":"2025","journal-title":"Trends Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/cid\/ciac949","article-title":"Weight and Metabolic Changes After Switching from Tenofovir Alafenamide\/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)\/FTC + DTG, and TDF\/FTC\/Efavirenz to TDF\/Lamivudine\/DTG","volume":"76","author":"Bosch","year":"2023","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_30","first-page":"765","article-title":"Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen","volume":"16","author":"Tse","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3350\/cmh.2024.1070","article-title":"Impacts of Metabolic Syndrome Diseases on Long-Term Outcomes of Chronic Hepatitis B Patients Treated with Nucleos(t)Ide Analogues","volume":"31","author":"Huang","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Li, J., Xu, L., Rui, F., Tran, S., Tsai, P.-C., Tan, Y., Toyoda, H., Zeng, Q.-L., Trinh, H., and Hsu, Y.-C. (2025). Type 2 Diabetes Mellitus as an Independent Predictor of Significant Fibrosis in Treatment-Na\u00efve Chronic Hepatitis B Patients with Concurrent Hepatic Steatosis. Hepatology.","DOI":"10.1097\/HEP.0000000000001442"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"107256","DOI":"10.4239\/wjd.v16.i7.107256","article-title":"Chronic Hepatitis B with Type 2 Diabetes Mellitus: Association between Glycemic Control and Liver Fibrosis","volume":"16","author":"Luo","year":"2025","journal-title":"World J. Diabetes"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/1826\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:45:20Z","timestamp":1772631920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/1826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jcm15051826"],"URL":"https:\/\/doi.org\/10.3390\/jcm15051826","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]}}}